Navigation Links
Pharmasset Appoints Michael Rogers as Chief Development Officer
Date:11/1/2007

e treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in the Americas and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is enrolling a 28-day Phase 1 clinical trial in combination with Pegasys(R) and Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Lexiva(R), Agenerase(R), Mepron(R) and Malarone(R) are registered trademarks of GlaxoSmithKline.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: (609) 613-4125

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that our collaboration with Roche will not continue or will not be successful, the risk that the on-going or anticipated clinical trials for any one or more of our product candidates will not be successful or will not provide meaningful data and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking stat
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , May 20, 2013  (PSHR) Pacific ... naturally based products across a broad range of ... has retained investor relations firm, BlueWater Advisory Group, ... return to trading process, and to direct the ... initiation. Matthew Mills ...
(Date:5/20/2013)... , May 20, 2013   BioHealth ... focusing on commercializing market-relevant biohealth innovations and increasing ... Maryland , today announced its selection of ... (EIR) for BHI at the National Institutes of ... Institute (NHLBI). Dr. Aiyar will help advance ...
(Date:5/20/2013)... May 20, 2013 Interventional cardiologist Tony ... General Hospital (AGH) Cardiovascular Institute have helped pioneer ... artery disease (CAD) over the past three decades, ... balloon angioplasty and coronary artery stent implantation. , Today, ... play a prominent role in the study of a ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Kitware, a ... visualization tool that enables the exploration of hospital ... created in response to the recent release of “Medicare ... the top 100 most-billed procedures from the Centers for ... costs for similar procedures at hospitals across the country ...
Breaking Biology Technology:Pacific Shore Holdings Retains Investor Relations Firm 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 3BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 4Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 3Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 4Kitware Enables Interactive Exploration of CMS Medicare Data 2
... December 3 On,November 28, Essilor cancelled 1,600,000 shares, ... dilutive impact of Oceane bond conversions and,the Company,s stock ... These latest cancellations concerned shares acquired under the 6.9,million ... on July,15, 2008 to offset the dilutive impact of ...
... Dec. 2 Transgenomic,Inc. (OTC Bulletin Board: ... Board: PWRM) today announced that Transgenomic has ... rights for Power3 Medical,s Neurodegenerative,Biomarkers, which include ... disease. Transgenomic plans to offer NuroPro(R) ...
... 2 Bionovo, Inc.,(Nasdaq: BNVI ), a pharmaceutical company ... the areas of women,s health and,cancer, announced that Isaac Cohen, Chairman ... at the 20th Annual Piper Jaffray Health,Care Conference at 8 a.m. ... at,the New York Palace Hotel in New York City. , ...
Cached Biology Technology:Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 2Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 3Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 4Bionovo to Present at the Piper Jaffray Healthcare Conference 2
(Date:5/17/2013)... Atlanta residents of all ages will celebrate the ... impact on our daily lives during the inaugural ... engineers and educators from local museums, corporations, K-12 ... than 40 different events for children and adults ... http://atlantasciencefestival.org . , The annual Atlanta ...
(Date:5/17/2013)... in Efficient and Sustainable Global Logistics Operations) is aiming ... the efficiency of intermodal loading systems and the boosting ... 29 European organisations with experience in the logistics sector ... totalling 17,000,000 and a duration of three and a ... develop the semantic components and ontologies shared by the ...
(Date:5/17/2013)... team of scientists using a new X-ray method recorded ... frog embryo in greater detail than ever before., This ... and the search for new treatments for genetic diseases., ... Technologie in Germany, in collaboration with the Advanced Photon ... Laboratory, released the most precise depiction ever of the ...
Breaking Biology News(10 mins):First Atlanta Science Festival set for 2014 2New logistics services that will cut energy consumption and CO2 emissions 2New X-ray method shows how frog embryos could help thwart disease 2
... birth to develop the ability to determine sunrise and ... of Chicago shows. The research sheds new light ... behaviors, according to Brian Prendergast, associate professor in psychology ... paper published April 27 in the journal PLoS One. ...
... to investigate such things as how Pacific Northwest forests ... by pests and diseases is being pruned back to ... located in a 500-year-old forest near Stevenson in southwest ... Washington, the Forest Service,s Pacific Northwest Research Station and ...
... An international team of scientists, led by researchers at ... have developed a new method for discerning the functions ... functional networks that reveal how gene products interact to ... in the April 29 issue of the journal Cell. ...
Cached Biology News:From the beginning, the brain knows the difference between night and day 2Era of canopy crane ending; certain research and education activities remain 2Era of canopy crane ending; certain research and education activities remain 3As the worm turns, its secrets are revealed 2
...
Bovine Renal Artery Endothelial Cells (BRAEC) (>500,000 cells)...
RECK (F-20)...
... polyclonal to Peroxiredoxin 1 Peroxiredoxin ... whose mammalian members have been known ... and apoptosis. Many isoforms (about 50 ... amino acid sequence homology, particularly amino-terminal ...
Biology Products: